Search Results for "Simponi"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Simponi. Results 1 to 7 of 7 total matches.
See also: golimumab
Flowchart: Rheumatoid Arthritis Treatment (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
sarilumab Simponi Riabni Xeljanz upadacitinib Truxima tofacitinib tocilizumab TNF inhibitors sulfasalazine ...
View the Flowchart: Rheumatoid Arthritis Treatment
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
– Simponi
(Janssen)
Simponi Aria
50 mg/0.5 mL, 100 mg/
mL syringes and
auto-injectors
50 mg single ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
), golimumab (Simponi), or
infliximab (Remicade, and biosimilars), the integrin
receptor antagonist ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
– Simponi (Janssen) 50 mg/0.5 mL, 100 mg/1 mL Induction: 200 mg SC at week 0, then 100 mg SC 12,113.30
auto ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Golimumab3 – Simponi
(Janssen)
50 mg/0.5 mL,
100 mg/1 mL auto-injectors;
50 mg/0.5 mL,
100 mg/1 mL ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
Golimumab4 – Simponi (Janssen) 50 mg/0.5 mL, 100 mg/mL syringes 50 mg SC once/month 5266.70
and auto ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
, and
biosimilars), adalimumab (Humira, and biosimilars),
and golimumab (Simponi) are FDA-approved for use ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction